China has the highest incidence of gastroesophageal cancer globally, and therapeutic options are limited. Only five targeted agents are approved for treatment—trastuzumab (Roche’s Herceptin,…
The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma…
Breast cancer is the most commonly diagnosed cancer in women in China. The disease has been managed primarily through chemotherapy in China, but several novel, premium-priced targeted therapies—…
Acute myeloid leukemia (AML) is the most common form of adult leukemia and has the lowest five-year overall survival rates of all blood cancers. Historically, the treatment of AML in China is…
China’s psoriasis market has grown significantly over the last few years owing to the growing use of biologics to treat the disease. We expect the market to expand further over the 2021-2031…
Rheumatoid arthritis (RA) is a chronic and progressive autoimmune disease that primarily affects the joints. China has the highest number of RA patients in the world, and disease management is…
Heart failure presents a major public health burden in China. With a rapidly rising urban population and a growing trend of unhealthy lifestyle, heart failure is expected to affect a sizeable…
Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…
Bladder cancer is the eighth most commonly diagnosed cancer in China. The bladder cancer therapy market is set to enter a competitive and dynamic period of rapid growth, fueled by one of the most…
Of the four subtypes of non-Hodgkin’s lymphoma (NHL), diffuse large B-cell lymphoma (DLBCL) is the most common in China. Rituximab (Roche’s MabThera, biosimilars) continues to dominate China’…
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-…
Multiple sclerosis (MS), a chronic immune-mediated disease of the nervous system, is classified as a rare disease in China because of its low prevalence there. Traditionally, patients suffering…
China has a high disease burden of human immunodeficiency virus (HIV), but patients are well managed by different classes of antiretroviral therapies (ARTs), including single-tablet regimens (e.g…
Non-alcoholic steatohepatitis (NASH) is a chronic disease that causes extensive and potentially fatal liver fibrosis; it is a leading cause of liver transplant. Significant increases in rates of…
The treatment landscape for COVID-19 is rapidly evolving, as such, intense research is focused on approaches designed to reduce viral load and/or improve outcomes in hospitalized patients infected…